Article

A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the Proliferation, Immune response and RNA splicing modules in breast cancer

Department of Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Breast cancer research: BCR (Impact Factor: 5.88). 12/2008; 10(6):R93. DOI: 10.1186/bcr2192
Source: PubMed

ABSTRACT Several gene expression signatures have been proposed and demonstrated to be predictive of outcome in breast cancer. In the present article we address the following issues: Do these signatures perform similarly? Are there (common) molecular processes reported by these signatures? Can better prognostic predictors be constructed based on these identified molecular processes?
We performed a comprehensive analysis of the performance of nine gene expression signatures on seven different breast cancer datasets. To better characterize the functional processes associated with these signatures, we enlarged each signature by including all probes with a significant correlation to at least one of the genes in the original signature. The enrichment of functional groups was assessed using four ontology databases.
The classification performance of the nine gene expression signatures is very similar in terms of assigning a sample to either a poor outcome group or a good outcome group. Nevertheless the concordance in classification at the sample level is low, with only 50% of the breast cancer samples classified in the same outcome group by all classifiers. The predictive accuracy decreases with the number of poor outcome assignments given to a sample. The best classification performance was obtained for the group of patients with only good outcome assignments. Enrichment analysis of the enlarged signatures revealed 11 functional modules with prognostic ability. The combination of the RNA-splicing and immune modules resulted in a classifier with high prognostic performance on an independent validation set.
The study revealed that the nine signatures perform similarly but exhibit a large degree of discordance in prognostic group assignment. Functional analyses indicate that proliferation is a common cellular process, but that other functional categories are also enriched and show independent prognostic ability. We provide new evidence of the potentially promising prognostic impact of immunity and RNA-splicing processes in breast cancer.

Download full-text

Full-text

Available from: Andrew E Teschendorff, Aug 10, 2015
0 Followers
 · 
330 Views
  • Source
    • "Galon and colleagues (2006) reported that gene expression profiling of tumor infiltrating lymphocytes in colorectal cancer was a better predictor of patient survival than standard histopathological methods, with upregulated genes associated with Type I (Th1) immune response strongly associated with lower recurrence rates ( p < 0.05). Gene expression arrays of cancer cells have similarly demonstrated a correlation between an ''immunologic signature'' of immune responseassociated genes and improved prognosis, as demonstrated extensively in the literature for breast cancer, lung cancer, and melanoma (Bogunovic et al., 2009; Mandruzzato et al., 2006; Reyal et al., 2008; Roepman et al., 2009; Staaf et al., 2010; Teschendorff et al., 2007). To date, these immunologic signatures have not been validated outside of clinical protocols. "
    [Show abstract] [Hide abstract]
    ABSTRACT: As vaccines evolve to be a more common treatment for some cancers, further research is needed to improve the process of developing vaccines and assessing response to treatment. Vaccinomics involves a wide-ranging integration of multiple high throughput technologies including transcriptional, translational, and posttranslational population-based assessments of the human genome, transcriptome, proteome, and immunome. Vaccinomics combines the fields of immunogenetics, immunogenomics, immunoproteomics, and basic immunology to create vaccines that are tailor made to an individual or groups of individuals. This broad range of omics applications to tumor immunology includes antigen discovery, diagnostic biomarkers, cancer vaccine development, predictors of immune response, and clinical response biomarkers. These technologies have aided in the advancement of cancer vaccine development, as illustrated in examples including NY-ESO-1 originally defined by SEREX, and HER2/neu peptides analyzed via high-throughput epitope prediction methods. As technology improves, it presents an opportunity to improve cancer immunotherapy on a global scale, and attention must also be given to utilize these high-throughput methods for the understanding of cancer and immune signatures across populations.
    Omics: a journal of integrative biology 07/2011; 15(9):579-88. DOI:10.1089/omi.2010.0149 · 2.73 Impact Factor
  • Source
    • "Next, using gene-set #2, an unsupervised clustering of these tumours identified two possible subclasses distinguished by the expression level of several transcripts in these processes (Figure 3A). The expression level of immune response genes has recently been shown to provide prognostic value for sporadic ER-negative breast tumours (Teschendorff et al, 2007) and this biological process seems to be commonly present in breast cancer prognosis signatures (Reyal et al, 2008). Examination of gene-set #2 and the signature of Teschendorff et al (2007) identified 18 genes in common, which is higher than the number expected by chance (P-value o10 À7 ). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Gene expression profiling has distinguished sporadic breast tumour classes with genetic and clinical differences. Less is known about the molecular classification of familial breast tumours, which are generally considered to be less heterogeneous. Here, we describe molecular signatures that define BRCA1 subclasses depending on the expression of the gene encoding for oestrogen receptor, ESR1. For this purpose, we have used the Oncochip v2, a cancer-related cDNA microarray to analyze 14 BRCA1-associated breast tumours. Signatures were found to be molecularly associated with different biological processes and transcriptional regulatory programs. The signature of ESR1-positive tumours was mainly linked to cell proliferation and regulated by ER, whereas the signature of ESR1-negative tumours was mainly linked to the immune response and possibly regulated by transcription factors of the REL/NFkappaB family. These signatures were then verified in an independent series of familial and sporadic breast tumours, which revealed a possible prognostic value for each subclass. Over-expression of immune response genes seems to be a common feature of ER-negative sporadic and familial breast cancer and may be associated with good prognosis. Interestingly, the ESR1-negative tumours were substratified into two groups presenting slight differences in the magnitude of the expression of immune response transcripts and REL/NFkappaB transcription factors, which could be dependent on the type of BRCA1 germline mutation. This study reveals the molecular complexity of BRCA1 breast tumours, which are found to display similarities to sporadic tumours, and suggests possible prognostic implications.
    British Journal of Cancer 10/2009; 101(8):1469-80. DOI:10.1038/sj.bjc.6605275 · 4.82 Impact Factor
  • Source
Show more